文献速递系统性红斑狼疮

系统性红斑狼疮中超声确认附着点炎的患病率及临床关联

Prevalence and clinical associations of ultrasound-confirmed enthesitis in systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

该回顾性分析纳入106例符合EULAR/ACR分类标准的SLE患者行关节超声,31例(29.2%)发现附着点炎;中位随访10.0年(病例)与12.4年(对照)期间,附着点炎组肾脏受累比例更低(22.6% vs 46.5%,P=0.028),B细胞清除治疗失败更常见(75.0% vs 0%)。

要点

  • SLE临床关节活跃患者中超声确认附着点炎占29.2%(31/106)。
  • 附着点炎组肾脏受累比例低于无附着点炎对照组(22.6% vs 46.5%,P=0.028)。
  • 附着点炎组B细胞清除治疗失败比例高于对照组(75.0% vs 0%)。

核心结论

  • 在临床关节活跃的SLE患者中,超声证实的附着点炎是相当常见的发现,可能标志一种肾脏受累更少、关节炎更多且对抗CD20治疗反应低的独特疾病表型。

研究设计与样本

  • 回顾性分析意大利Careggi大学医院狼疮单元SLE队列,纳入400例符合EULAR/ACR分类标准的SLE患者,其中106例因关节压痛和/或肿胀接受关节超声检查以评估附着点炎。

主要发现

  • 106例接受超声检查的患者中31例(29.2%)发现附着点炎,71例无超声附着点炎者作为对照,4例因缺乏随访数据被排除。
  • 病例组与对照组在疾病初发时的临床和实验室特征相当。
  • 病例组中位随访10.0年(IQR 8.3-23.3),对照组中位随访12.4年(IQR 7.2-13.3)。
  • 随访期间附着点炎组肾脏受累比例低于对照组(22.6% vs 46.5%,P=0.028)。
  • 附着点炎组B细胞清除治疗失败比例高于对照组(75.0% vs 0%)。

关键数值与推荐

  • 附着点炎患病率为31/106(29.2%)。
  • 肾脏受累:附着点炎组22.6% vs 无附着点炎对照组46.5%(P=0.028)。
  • B细胞清除治疗失败:附着点炎组75.0% vs 对照组0%。

临床怎么用

  • 作者认为SLE中的附着点炎可能是独特疾病表型的标志,可能需定制化治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the prevalence of US-confirmed enthesitis in a cohort of patients with SLE and to analyse the clinical associations to enthesitis during the course of SLE. METHODS: In a retrospective analysis of the SLE cohort of the Lupus Unit of the Careggi University Hospital, US examinations of SLE patients presenting with tender and/or swollen joints were retrieved to assess the presence of enthesitis. Patients with US-proven enthesitis were compared with SLE controls with tender and/or swollen joints who showed no US evidence of enthesitis. Clinical and laboratory features were compared at disease onset and during follow-up. RESULTS: A total of 400 patients fulfilling EULAR/ACR classification criteria for SLE were assessed. Of these, 106 underwent articular US examination. Evidence of enthesitis was found in 31/106 (29.2%) patients. Seventy-one patients without US-enthesitis were included as controls; four were excluded due to lack of follow-up data. Laboratory and clinical features were comparable between cases and controls at disease onset. Throughout a median follow-up of 10.0 (interquartile range [IQR] 8.3-23.3) years for cases and 12.4 (IQR 7.2-13.3) years for controls, patients with enthesitis were less likely to develop renal involvement (22.6% vs 46.5%, P = 0.028) and failed B cell depletion more frequently (75.0% vs 0%). CONCLUSION: In SLE patients with clinically active joints, US-proven enthesitis is a fairly common finding. Enthesitis in SLE could be the hallmark of a distinct disease phenotype with less renal involvement, more arthritis and low response to anti-CD 20 therapy, potentially requiring a tailored treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Fagni F, Bettiol A, Silvestri E, et al. Prevalence and clinical associations of ultrasound-confirmed enthesitis in systemic lupus erythematosus. Rheumatology (Oxford). 2023. PMID: 36929914. doi:10.1093/rheumatology/kead123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。